Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma

Elizabeth N. Bearrick, Vignesh Packiam, Bimal Bhindi, Christine M. Lohse, John C. Cheville, Ross J. Mason, Matthew Tollefson, Susan Harrington, Haidong Dong, Alexander S. Parker, Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich

Résultat de recherche: Articleexamen par les pairs

3 Citations (Scopus)

Résumé

Background: Clinical and pathological factors alone have limited prognostic ability in patients with metastatic clear cell renal cell carcinoma (ccRCC). Bim, a downstream pro-apoptotic molecule in the PD-1 signaling pathway, has recently been associated with survival in other malignancies. We sought to determine if tissue biomarkers including Bim, added to a previously reported clinical metastases score, improved prediction of cancer-specific survival (CSS) for patients with metastatic ccRCC. Methods: Patients with metastatic ccRCC who underwent nephrectomy between 1990 and 2004 were identified using our institutional registry. Sections from paraffin-embedded primary tumor tissue blocks were used for immunohistochemistry staining for Bim, PD-1, B7-H1 (PD-L1), B7-H3, CA-IX, IMP3, Ki67, and survivin. Biomarkers that were significantly associated with CSS after adjusting for the metastases score were used to develop a biomarker-specific multivariable model using a bootstrap resampling approach and forward selection. Predictive ability was summarized using a bootstrap-corrected c-index. Results: The cohort included 602 patients: 192 (32%) with metastases at diagnosis and 410 (68%) who developed metastases after nephrectomy. Median follow-up was 9.6 years (IQR 4.2–12.8), during which 504 patients died of RCC. Bim, IMP3, Ki67, and survivin expression were significantly associated with CSS after adjusting for the metastases score, and were eligible for biomarker-specific model inclusion. After variable selection, high Bim (hazard ratio [HR] = 1.44; 95% confidence interval [CI] 1.16–1.78; P <0.001), high survivin (HR = 1.35; 95% CI 1.08–1.68; P = 0.008), and the metastases score (HR = 1.13 per 1 point; 95% CI 1.10–1.16; P <0.001) were retained in the final multivariable model (c-index = 0.69). Conclusion: We created a prognostic model combining the clinical metastases score and 2 primary tumor tissue expression biomarkers, Bim and survivin, for patients with metastatic renal cell carcinoma who underwent nephrectomy.

Langue d'origineEnglish
Pages (de-à)135.e1-135.e8
JournalUrologic Oncology: Seminars and Original Investigations
Volume39
Numéro de publication2
DOI
Statut de publicationPublished - févr. 2021

Note bibliographique

Publisher Copyright:
© 2020 Elsevier Inc.

ASJC Scopus Subject Areas

  • Oncology
  • Urology

PubMed: MeSH publication types

  • Journal Article

Empreinte numérique

Plonger dans les sujets de recherche 'Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma'. Ensemble, ils forment une empreinte numérique unique.

Citer

Bearrick, E. N., Packiam, V., Bhindi, B., Lohse, C. M., Cheville, J. C., Mason, R. J., Tollefson, M., Harrington, S., Dong, H., Parker, A. S., Boorjian, S. A., Thompson, R. H., & Leibovich, B. C. (2021). Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 39(2), 135.e1-135.e8. https://doi.org/10.1016/j.urolonc.2020.08.028